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Abstract
Background: Estrogen is known to play role in temporomandibular joint (TMJ) disorders and
estrogen effects can be mediated by estrogen receptor (ER) alpha present in the TMJ. Cells
expressing the estrogen receptor ERalpha are present in the temporomandibular joint (TMJ) but
changes in expression due to estrogen and inflammation have not been characterized. In this study,
ERalpha protein content and the number of cells expressing ERalpha was measured in 17 beta-
estradiol-treated rats after inflammation was induced in the TMJ.
Methods: Sixteen ovariectomized female rats were divided into two groups such that one group
received 17 beta estradiol (E2) and the other was given vehicle (VEH). Groups were then
subdivided further, one received injections of saline and the other received Complete Freund's
adjuvant (CFA) within the superior joint space of the TMJ. Thus the four groups include no E2/
saline, E2/saline, no E2/CFA and E2/CFA. After treatment, the rats were sacrificed, and the TMJ
anterior, disc, retrodiscal and synovial tissues were analyzed by western blot and
immunocytochemistry. Positive stained cells were counted using a Nikon epifluorescent
microscope.
Results: The western blot showed that ERalpha protein significantly decreased with inflammation.
The number of ERalpha-positive cells in the TMJ was not affected by inflammation or 17 beta-
estradiol with exception of the retrodiscal tissue. In the retrodiscal tissue 17 beta-estradiol
significantly decreased the number of ERalpha-positive cells but only in a non-inflamed joint.
Conclusions: In conclusion, inflammation and 17 beta-estradiol can modulate ERalpha expression
in the TMJ but the effects are tissue specific.
Background
Epidemiological studies have shown that during their
reproductive years, women experience a higher frequency
of temporomandibular joint disorders than males with a
ratio of = 1.5- 2 [1]. It has been postulated that estrogen
could be the primary molecule leading to the higher fre-
quency of TMJ disorders in women. Endogenous estrogen
affects the remodeling processes within the TMJ [2,3] pos-
sibly by changing the extracellular matrix in the joint [4]
or by changing bone volume [2]. Such changes can result
in internal derangement of the TMJ. Estrogen modulation
of matrix metalloproteinase (MMP) expression has also
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been observed in the cartilage of the TMJ [5,6]; high levels
of MMP have been reported to play a role in TMJ osteoar-
thritis [7,8]. Moreover, the level of estrogen in the syno-
vial fluid has been correlated to the severity of arthritis in
postmenopausal women [9], and in animal models estro-
gen has been shown to modulate inflammation in the
TMJ [10,11].
17 β-estradiol is the most potent and dominant form of
estrogen in the human female, having biological effects
through binding the estrogen receptor alpha (ERα) and
beta (ERβ) [12]. ERα and ERβ acts via binding to the DNA
[13] or by having biological effects through interacting
with various kinases, such as mitogen-activated protein
kinase, phosphatidylinositol-3 kinase or tyrosine kinase
[12]. Also both receptors can interact with membrane-
associated molecules such as ion channels and G protein-
coupled receptors to alter the physiology of the cell [12].
The wide distribution of the estrogen receptors ERα and
ERβ in the thymus [14,15], bone marrow [16] and spleen
[17] suggests that it plays a modulatory role in the
immune system, such as modulating differentiation, acti-
vation, proliferation and antibody production from lym-
phoid cells [18]. Immune responses are important in joint
disorders and an alteration in ERα and ERβ expression
would have an impact on how estrogen affects the
immune response in the TMJ.
In particular, ERα was found in the articular cartilage and
subchondral bone of TMJ which implies that estrogen
directly acted on the cells in the TMJ tissue to alter the
gene expression and cellular physiology [19]. In contrast
to the ERα expression in the rat, ERα nuclear staining was
not detected in the bone, cartilaginous or connective tis-
sues of the human or baboon TMJ, but it was present in
the immune cells such as macrophage and lymphocytes
[20,21].
In addition ER knockout studies have shown a major role
for ERα in immune modulation [22,23]. Because ERα is
present in the immune cells in the human TMJ [20,21], a
likely target of 17 β-estradiol in the human TMJ is ERα-
positive immune cells. Furthermore ER-α gene polymor-
phisms is associated with a predisposition to TMJ disor-
ders [24]. Such data from both animal and clinical studies
support a significant role of ERα in the increased inci-
dence of TMJ inflammation [24,25].
In an intact rat 17 β-estradiol and progesterone concentra-
tions change during the estrus cycle [26]. Multiple fluctu-
ating hormones could complicate our understanding of
how 17 β-estradiol modulates estrogen receptor expres-
sion. Hormone administration in overiectomized animals
allows us to study the effect of 17 β-estradiol, avoiding
fluctuating levels. Thus, our study was focused on the
effect of a single, physiological concentration of 17 β-
estradiol. This concentration of 17 β-estradiol was equal
to that observed during the estrus cycle [26].
The level of receptor will determine the cellular sensitivity
to 17 β-estradiol, because this hormone acts primarily
through the estrogen receptor(s) [27]. This paper particu-
larly focuses on ERα expression in response to17β-estra-
diol and inflammation. The aim of the present study is to
first quantify the tissue content of ERα in the female rat
TMJ, and second, to determine whether changes in the
ERα expression in the TMJ result from alterations in
inflammation or the concentration of 17β-estradiol.
Methods
Animals and tissue preparation
The Baylor College of Dentistry Institutional Animal Care
and Use Committee approved the experimental protocol.
Female Sprague Dawley rats (~230 gm) were ovariect-
omized by Harlan Industries, Houston TX. Upon arrival,
the rats were housed individually and kept on a 14:10 h
light/dark cycle with lights on at 0600 h. All the rats were
anesthetized with ketamine (45 mg/kg) and rompun (4.8
mg/kg). Using sterile technique, the rats were implanted
with primed, 14-day Alzet mini-osmotic pumps dispens-
ing vehicle, polyethylene glycol (no estrogen replacement
control group) or 750 ng/day of 17β-estradiol benzoate.
These animals were then subdivided further; one group
received bilateral injections of 0.9% saline (30 μl) and the
other group received an injection of 30 μg (30 μl) of com-
plete Freund's adjuvant (CFA) within the superior joint
space of the TMJ just above the disc. The animals were
removed from their cages and sacrificed with an overdose
of CO2 after 48 h. The animals were decapitated; blood
collected and the heads were placed in plastic bags and
submerged in ice water. For western analysis, the TMJ
anterior, disc, retrodiscal and synovium were dissected
from one side by performing a superficial, horizontal skin
incision parallel and just inferior to the zygomatic arch.
The masseter and temporalis muscles were cut away from
the arch and the ramus of the mandible so that the arch
could be removed with ronjeurs. The neck of the condyle
was grasped with hemostats and the condylar neck frac-
tured to allow removal of any remaining musculature and
access to the anterior, disc, retrodiscal and synovial tis-
sues. Dissected TMJ tissue was excised from the posterior
neck of the condyle, and all anterior tissue, articular disc,
retrodiscal tissue and synovium were removed, placed in
liquid nitrogen and stored at -80°C. For histological anal-
ysis, a 0.5 cm cube of TMJ tissue centered on the condyle
was removed, en bloc, from the other side and placed in
4% paraformaldehyde at 4°C overnight. The tissue was
then decalcified in 10% EDTA for 2 weeks, embedded in
paraffin wax and 8 μm sections were cut and mounted onReproductive Biology and Endocrinology 2009, 7:155 http://www.rbej.com/content/7/1/155
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Superfrost glass slides (Fisher Scientific, Pittsburgh, PA)
for immunohistochemical or hematoxylin and eosin
staining.
Quantitation of hormone levels
17 β-estradiol was quantitated in the blood plasma by
first, vigorously mixing 0.5 ml of plasma with 5 ml of
ether. Second, the solution was frozen in an ethanol, dry
ice bath and the ether phase decanted. The ether phase
contains the lipid soluble hormones. The ether was evap-
orated and the remaining residue suspended in RIA buffer
supplied by the manufacturer. The concentration of 17 β-
estradiol was quantitated following the manufactures
directions (ICN Biomedicals, Costa Mesa, CA).
Western blot analysis
The previously isolated, frozen TMJ anterior, disc, retro-
discal and synovial tissues were homogenized in ice-cold
protein-extraction buffer (75 mM potassium acetate pH
7.4, 300 mM NaCl, 10 mM EDTA, .25% Triton X-100,
protease inhibitors), centrifuged at 7500 g for 15 min at
4°C, and the resulting supernatant was collected and
stored at -20°C. Each sample was tested for protein con-
tent by standard BCA assay (Thermo Fisher Scientific,
Rockford, IL); 10 μg of total protein was loaded onto a
SDS PAGE, separated by electrophoresis, transferred to a
membrane, and the membrane was blocked with 1.5% v/
v BSA in TBS-T (50 mM Tris-HCl pH 7.5, 150 mM NaCl,
0.05% Tween 20) for 2 h at room temperature. After
blocking, the ERα mouse monoclonal antibody (Thermo
Fisher Scientific) was added at a dilution of 1:1000 over-
night at 4°C. The membrane was then incubated for 2 h
with a goat anti-mouse secondary antibody conjugated to
horseradish peroxidase. The products were detected by
means of an enhanced chemiluminescence light detection
kit (Bio-Rad, Hercules, CA). After detection of the ERα
band the blot was stripped according to the manufactures
directions with Erase-It (Thermo Fischer Scientific, Rock-
ford, IL) and re-probed with a β-actin antibody (Cell Sig-
naling, Boston, MA) at a dilution of 1:000 followed by
addition of a goat anti-rabbit secondary, detection and
development of the film. The BioMax films (Kodak,
Rochester, New York) were developed, digitally scanned,
and the integrated optical density of the resulting bands
was collected and analyzed using Scion Image (Scion Cor-
poration, Frederick, MD).
Immunocytochemistry
The paraffin wax was removed from the tissue sections,
and then the sections were processed for staining with
hematoxylin and eosin or for immunohistochemistry.
Light microscope images were captured by Zeiss Axioplan.
Immunohistochemistry was completed by first quenching
endogenous peroxidase with 0.3% H2O2 in PBS for 30
min, blocking in 10% normal goat serum and PBS for 1 h
and then incubating the slide with two primary antibod-
ies; mouse anti-ERα antibody diluted to 1:250 (Thermo
Fisher Scientific) and goat polyclonal CD14 (Santa Cruz
Biotechnology) diluted to 1:100 overnight at 4°C. The
sections were subsequently treated with two fluorescent
conjugated secondary antibodies (goat anti-mouse Alexa
488 (Invitrogen, Carlsbad, CA) at 1:2000 dilution and
rabbit anti-goat Alexa 633 in PBS at 1:500 (Molecular
Probes) for an hour at room temperature. The sections
were rinsed and then cover-slipped with fluoromount-G
medium (Southern Biotech, Birmingham, AL) containing
DAPI counterstain. The total (DAPI positive) and ERα
positive cells (Alexa 488 positive) were counted on every
10th section to obtain a representative sample through the
entire TMJ region [28] using a Nikon epifluorescent
microscope. The images were also analyzed with a Leica
TCS-SP2 confocal microscope and arranged with Adobe
Photoshop.
Data and statistical analysis
The data were analyzed using two-way ANOVA using the
factors of hormone and inflammation. Data that showed
a significant group effect were further analyzed using a
Bonferroni post-hoc test. P-values of < 0.05 were consid-
ered to be statistically significant. The results were
expressed as the mean and standard error of the mean
(SEM).
Results
In the rat, Alzet pumps released 750 ng/day of 17 β-estra-
diol benzoate. This amount produced a plasma 17 β-estra-
diol concentration of approximately 20 pg/ml (Fig. 1), a
concentration that was significantly higher than ovariect-
omized rats receiving vehicle and was similar to the
amount of plasma 17 β-estradiol reported for rats during
the estrus cycle [26].
After performing a western blot on the samples from the
TMJ no significant change in ERα expression was found
due to administration of 17 β-estradiol in either the saline
(Fig 2A and 2B) or CFA (Fig. 2A and 2C) injected group.
The amount of ERα protein significantly decreased after
injection of CFA into both vehicle or 17 β-estradiol treated
rats (Fig. 2A).
Swelling was observed in the retrodiscal tissue of ovariec-
tomized rats injected with CFA (Fig. 3B). This was in con-
trast to the retrodiscal tissue of saline injected rats that had
no swelling (Fig. 3A). Similar levels of swelling were
observed in ovariectomized rats injected with vehicle or
17 β-estradiol that were then injected with CFA (data not
shown). Nuclear and cytoplasmic ERα immunostaining
was observed in the highly vascularized retrodiscal tissue
(Fig. 4) and in the synovial lining cells. Double stained
ERα and CD14 positive cells were found in the retrodiscalReproductive Biology and Endocrinology 2009, 7:155 http://www.rbej.com/content/7/1/155
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area (Fig. 4) and synovium of all four groups. These dou-
ble labelled cells were observed more in CFA injected
group as compared to saline group. When the primary
antibody was not added (negative control), no signal was
observed (data not shown).
ERα-positive cells were counted in the anterior, disc, ret-
rodiscal and synovial tissue, but few ERα-positive cells
were observed in the disc (Fig. 5A). Of the total cells
observed, the counts showed that 84% of the ERα-positive
stained cells were in the retrodiscal tissue, 13% of the cells
were in the anterior tissue and 3% in the synovium. 17 β-
estradiol (E2) treatment significantly decreased the
number of cells expressing ERα in the retrodiscal tissue of
rats with a non-inflamed TMJ (No E2/saline vs. E2/saline;
Fig. 5A). The number of cells expressing ERα in the
inflamed retrodiscal tissue of the TMJ was unchanged after
giving the rats 17 β-estradiol (No E2/CFA vs. E2/CFA). In
the retrodiscal tissue, CFA significantly increased the
number of ERα positive cells in those rats receiving 17 β-
estradiol (E2/saline vs. E2/CFA) but not in rats given vehi-
cle (No E2/saline vs. no E2/CFA; Fig. 5A). (Though there
was a trend showing a higher number of cells in the No E2
saline group, the number of cells expressing ERα did not
Concentration of 17 β-estradiol in the plasma of ovariect- omized female rats Figure 1
Concentration of 17  -estradiol in the plasma of ova-
riectomized female rats. Ovariectomized (OVX) rats 
were implanted with Alzet pumps dispensing 750 ng/day of E2 
or the same volume of the vehicle polyethylene glycol (no 
E2). OVX rats infused with no E2 or E2 were given a 30 μl 
intra-articular temporomandibular joint (TMJ) injection of 
saline or 30 μg complete Freund's adjuvant (CFA) seven days 
after pump implantation. Treatment groups consisted of 
OVX rats having their TMJ injected with saline (No E2/saline); 
OVX rats supplemented with E2 that had saline injected into 
their TMJ (E2/saline); OVX rats injected with CFA (No E2/
CFA) and OVX rats supplemented with E2 that had CFA 
injected into the TMJ (E2/CFA). 48 h following TMJ injection 
the animals were sacrificed and the concentration of E2 was 
measured in the plasma by radio-immunoassay. The histo-
gram shows the mean ± SEM concentration of 17 β-estradiol 
per ml of plasma from the pooled values of four animals per 
treatment group, * p < 0.05.
Western blot of protein isolated from the temporomandibu- lar joint (TMJ) of ovariectomized female rats treated with 17  β-estradiol Figure 2
Western blot of protein isolated from the temporo-
mandibular joint (TMJ) of ovariectomized female 
rats treated with 17  -estradiol. Ovariectomized (OVX) 
rats were given a physiological dose of (E2) or vehicle (No E2) 
using osmotic pumps and after 7 days of estrogen treatment 
the TMJ was injected with 30 μl of saline or 30 μg CFA. Pro-
tein from the TMJ anterior, disc, retrodiscal and synovial tis-
sues was isolated, 10 μg of protein was loaded in each lane of 
the gel and the western blot was probed with anti-ERα and 
then anti-β-actin. (A) Optical densities of the ERα specific 
band (65 kDa) were determined from the western blot and 
the optical density of the ERα specific band was normalized 
to the β-actin band. The normalized mean ± SEM optical den-
sity values are shown in the histogram. Each lane in panels B 
and C is a representative sample from one animal in each 
treatment group. ** = p < 0.01.
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significantly change in the anterior, disc or synovium of
the TMJ as a result of giving 17 β-estradiol or CFA (Fig.
5A). Also, the total number of cells in these tissues did not
change following 17 β-estradiol or CFA treatment (Fig.
5B).
Discussion
In these studies we administered 17 β-estradiol to ovariec-
tomized rats such that the plasma concentration of hor-
mone was physiological and similar to the concentration
observed during the rats estrus cycle [26]. In ovariect-
omized rats, treated with and without 17β-estradiol, injec-
tion of CFA into the TMJ induced swelling of the
retrodiscal tissue. Induction of inflammation decreased
the expression of ERα in the TMJ of rats injected with and
without 17β-estradiol. 17 β-estradiol reduced the number
of ERα positive cells in the retrodiscal tissue but only in
animals that did not have an inflammation, suggesting
first that 17 β-estradiol acts in a tissue specific manner in
the TMJ region and second that the inflammation can
alter the effect of estradiol.
Knowing that on western blots estrogen receptor levels
decreased in the TMJ region after injection of CFA, the
question arose as to whether this decrease was due to a
reduction in the number of cells expressing the receptor or
to a decrease in the number of receptors per cell. For this
reason we counted the number of cells expressing ERα. In
the anterior and synovial tissue the number of ERα posi-
tive cells in the No E2/saline group trended (showed a
trend to be) higher than in the No E2/CFA group, suggest-
ing the CFA induced a decrease in ERα levels, consistent
with the western results. Animals receiving 17 β-estradiol
had a decreased amount of ERα on a western blot after
Histology of sagittal section of a female rat temporomandibular joint Figure 3
Histology of sagittal section of a female rat temporomandibular joint. (A) Representative image of a vehicle treated 
OVX rat 48 h after injecting 30 μl of saline. (B) Representative image of a vehicle-treated ovariectomized (OVX) rat 48 h after 
injecting 30 μl of complete Freund's adjuvant in the upper joint space of the temporomandibular (TMJ). The TMJ was removed 
en bloc 48 h after injection, paraffin-embedded, sectioned at 8 μm and stained with hematoxylin and eosin. Sight of inflamed tis-
sue is indicated by black arrowheads. Size bar = 500 μm
Immunofluorescent staining of ERα and CD14 observed in  the retrodiscal tissue of the TMJ in all four treatment groups Figure 4
Immunofluorescent staining of ER  and CD14 
observed in the retrodiscal tissue of the TMJ in all 
four treatment groups. A) No E2/saline, B) No E2/CFA, 
C) E2/saline, D) E2/CFA. The sections were immunohisto-
chemically stained with mouse anti-ERα and goat polyclonal 
anti- CD14 primary antibodies followed by anti-mouse Alexa 
488 conjugated (green) and anti-goat Alexa 633 conjugated 
(red) secondary respectively. ERα nuclear with CD14 cyto-
plasmic staining (arrows), ERα cytoplasmic staining (arrow-
head), ERα nuclear staining (open arrowhead) and CD14 
staining (open arrow) were observed. Size bar for A, B, D = 
47.5 μm.; C = 50 μm.Reproductive Biology and Endocrinology 2009, 7:155 http://www.rbej.com/content/7/1/155
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Cell counts within the TMJ Figure 5
Cell counts within the TMJ. Quantitation of (A) ERα-containing cells and (B) the total number of cells within the temporo-
mandibular joint (TMJ). Rats were given a constant infusion of vehicle (No E2) or 17 β-estradiol (E2) using osmotic pumps for 
one week, and then the TMJ was injected with saline or 30 μg of CFA to produce four treatment groups: No E2/saline, No E2/
CFA, E2/saline, E2/CFA. The TMJ was removed en bloc 48 h after TMJ injection, paraffin-embedded, sectioned at 8 μm and 
immunostained for ERα (Alexa 488 positive) and counterstained with DAPI. The histogram shows the number of ERα-positive 
stained cells in each of the four tissues (i.e., anterior, disc, retrodiscal and synovial) for each treatment group. Counts included 
cells with cytoplasmic and nuclear ERα staining. Following staining, the number of DAPI-positive cells in each tissue region was 
counted for each treatment group. Bars on the histogram were generated from the cell counts of four different animals per 
treatment group whose values were pooled to give a mean ± SEM. * = p < 0.05.
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CFA injection, but the number of ERα positive cells
increased in the anterior and retrodiscal tissue. Whereas in
the synovium the number of ERα positive cells did display
a downward trend after CFA injection. Double stained
ERα and CD14 positive immune cells observed in the ret-
rodiscal area and synovium of all four groups suggest the
presence of ERα positive immune cells consistent with the
ERα-positive immune cells found in humans [20].
Another study also shows that the synovium is highly
populated with monocytes and macrophages [29]. Macro-
phage-like and fibroblast-like synoviocytes stain for both
ERα and ERβ [30-32]. Although few in number, the ERα
positive cells in the synovium might have much higher
amounts of ERα per cell than the retrodiscal tissue. In the
event that a majority of the ERα protein from the TMJ was
derived from the synovium we would see a decrease in
ERα after CFA injection, consistent with our western blot
results. Our results showing that different tissues had a
different response to 17 β-estradiol was consistent with
studies done on rat uterus, demonstrating the upregula-
tion of ERα in the stromal cells and its concurrent down-
regulation in the epithelia of the uterus in response to
estradiol [33]. Expression of the immune complex protein
C3 was shown to be upregulated in the uterine epithelial
cells in response to estradiol whereas expression in the
liver was unaffected by the same concentration of estrogen
[34]. In joint tissue 17 β-estradiol alters proteoglycan
metabolism differently depending on location [35].
In the retrodiscal tissue the number of ERα positive cells
increased or remained unchanged after CFA injection but
the amount of ERα in each cell may have decreased lead-
ing to a reduction in the ERα observed on the western
blot. To determine whether an increase in the expression
per cell results in a higher expression of estrogen receptor,
we needed to quantitate the fluorescent signal in each cell.
Unfortunately, the florescent signal faded rapidly and we
could not determine the intensity of staining per cell (i.e.
ERα expression per cell) and thus, we could not determine
what led to the decrease in estrogen receptor signal on the
western blot.
The number of cells expressing ERα in the retrodiscal tis-
sue was significantly lower in the 17 β-estradiol-treated
rat. In humans, the estrogen receptors are present on peri-
vascular immune cells (e.g., macrophages) in the TMJ
[20]. 17 β-estradiol treatment has been shown to modu-
late gene expression in the macrophages [36-38]. In vivo
studies have shown that macrophage proliferation
increases with an increased estrogen concentration in
female mice [39,40], implying that estrogen can increase
ERα levels though stimulation of macrophage prolifera-
tion. Since we did not see an increase in ERα positive cell
numbers, macrophage proliferation was not a likely cause
for the increased ERα expression. Another possible expla-
nation for the reduction in ERα expression may be that
17β-estradiol caused a down-regulation of gene expres-
sion [41] similar to previous studies that indicated 17β-
estradiol inhibits ERα expression in joint tissue [42].
Interestingly, this previous study also showed that inflam-
mation effectively blocked the inhibitory effect of 17β-
estradiol, consistent with our results in the retrodiscal tis-
sue [42].
Studies have also demonstrated decreased specific bind-
ing of radiolabeled 17β-estradiol with E2 treatment which
resulted in a depletion of cytosolic ER [43,44]. Down-reg-
ulation of estrogen receptor was suggested to involve
some transcriptional activation mechanisms such as pro-
teasome-mediated proteolysis activity [45,46].
Conclusions
A constant physiological concentration of 17 β-estradiol
effects ERα expression in a non-inflamed and inflamed
TMJ. But several questions remain such as what are the
effects of 17 β-estradiol on ERβ in the TMJ tissues and
what are the effects of progesterone or pregnancy levels of
17 β-estradiol. Future studies would need to focus on the
amount of receptor per cell in different tissues as well as
determine the effect of higher concentrations of 17 β-
estradiol such as that occuring during pregnancy (120 pg/
ml). These studies might help develop estrogenic medica-
tions for TMJ pain. Moreover, progesterone could impact
estrogen receptor expression and interact with 17 β-estra-
diol to alter its effects.
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